Compare Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. with Similar Stocks
Dashboard
1
High Management Efficiency with a high ROE of 11.75%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 9.23
3
High Debt company with Weak Long Term Fundamental Strength
4
Flat results in Dec 15
5
With ROE of 8.11%, it has a Fair valuation with a 1.08 Price to Book Value
6
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
HKD 3,481 Million ()
13.00
NA
5.46%
-0.14
7.52%
0.08
Revenue and Profits:
Net Sales:
26,267 Million
(Quarterly Results - Mar 2026)
Net Profit:
2,058 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-17.25%
0%
-17.25%
6 Months
-16.86%
0%
-16.86%
1 Year
-8.71%
0%
-8.71%
2 Years
-31.02%
0%
-31.02%
3 Years
-38.52%
0%
-38.52%
4 Years
-22.97%
0%
-22.97%
5 Years
-25.85%
0%
-25.85%
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.06%
EBIT Growth (5y)
-0.24%
EBIT to Interest (avg)
9.23
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.57
Tax Ratio
16.19%
Dividend Payout Ratio
44.72%
Pledged Shares
0
Institutional Holding
0.14%
ROCE (avg)
15.88%
ROE (avg)
11.75%
Valuation key factors
Factor
Value
P/E Ratio
13
Industry P/E
Price to Book Value
1.08
EV to EBIT
13.47
EV to EBITDA
11.05
EV to Capital Employed
1.07
EV to Sales
0.56
PEG Ratio
NA
Dividend Yield
0.43%
ROCE (Latest)
7.96%
ROE (Latest)
8.11%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Jun 2011
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.14%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
26,267.00
24,028.00
9.32%
Operating Profit (PBDIT) excl Other Income
2,435.20
2,474.40
-1.58%
Interest
116.70
108.60
7.46%
Exceptional Items
-3.90
-10.30
62.14%
Consolidate Net Profit
2,058.00
1,985.90
3.63%
Operating Profit Margin (Excl OI)
92.70%
92.30%
0.04%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 9.32% vs -3.75% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 3.63% vs -10.16% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
83,991.00
81,106.10
3.56%
Operating Profit (PBDIT) excl Other Income
4,400.70
4,645.10
-5.26%
Interest
463.10
476.40
-2.79%
Exceptional Items
-23.30
-377.60
93.83%
Consolidate Net Profit
3,319.40
3,253.50
2.03%
Operating Profit Margin (Excl OI)
40.10%
44.80%
-0.47%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 3.56% vs -2.36% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 2.03% vs -30.87% in Dec 2024
About Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. 
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






